Previous 10 | Next 10 |
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX PR Newswire The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with Por...
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference PR Newswire Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophage...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "C...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Luci...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program PR Newswire NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and ...
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Tes...
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors PR Newswire The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participant...
News, Short Squeeze, Breakout and More Instantly...
PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Con...
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results PR Newswire Quarterly EsoGuard ® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering ...
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall PR Newswire EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck ® unaffected by recall and remains the gold standa...